MacroGenics Announces Positive Results from Pivotal Phase 3 SOPHIA Study of Margetuximab
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
MacroGenics (MGNX) PT Raised to $40 at SunTrust Robinson Humphrey
February 6, 2019 1:30 PM ESTSunTrust Robinson Humphrey analyst Peter Lawson raised the price target on MacroGenics (NASDAQ: MGNX) to $40.00 (from $28.00) while maintaining a Buy rating.
... MoreMacrogenics (MGNX) Adds to Gains, Up 140%
February 6, 2019 9:06 AM ESTMacrogenics (NASDAQ: MGNX) Adds to Gains, Up 140%
... MoreMacrogenics (MGNX) Could Trade to $2B+ Valuation - Evercore ISI
February 6, 2019 8:47 AM ESTEvercore ISI analyst Umer Raffat said a $2 billion+ valuation for Macrogenics (NASDAQ: MGNX) is 'very likely' as SOPHIA hits.
Macrogenics (MGNX) Climbs 100% After Reporting Positive Results from Pivotal Phase 3 SOPHIA Study of Margetuximab
February 6, 2019 7:55 AM ESTMacrogenics (NASDAQ: MGNX) Climbs 100% After Reporting Positive Results from Pivotal Phase 3 SOPHIA Study of Margetuximab
... More